EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study

Zhuang Tian iD, Xiaoyan Li iD, Liwen Li iD, Qing Zhang iD, Jian'an Wang iD, Yunqi Shi, Daoquan Peng iD, Wei Ma iD, Ping Yang iD, Xiang Cheng iD, Wei Jin iD, Fang Wang iD und 4 weitere

Journal of the American Heart Association · 02.06.2026 · 15 (11)

DOI: 10.1161/jaha.125.046251 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 02.06.2026. Verfasst von Zhuang Tian und 15 weiteren Autor:innen. Beteiligte Einrichtung: Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Uracil, Ventricular Outflow Obstruction, Left, Cardiovascular Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long‐term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown.

Methods

Patients who completed the 30‐week, double‐blind, placebo‐controlled treatment period in EXPLORER‐CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM), with no active safety concerns, were eligible to enter the long‐term extension period to receive 48‐week mavacamten treatment. Patients previously on mavacamten continued mavacamten (dose at week 30; mavacamten–mavacamten group); patients previously on placebo received mavacamten (starting dose, 2.5 mg once daily; placebo–mavacamten group). Key efficacy end points included change from baseline in echocardiographic measures, New York Heart Association functional class, 23‐item Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. Analyses were descriptive; no between‐group hypothesis testing was performed.

Results

Seventy‐nine patients (mean age, 51.6 years; 27.8% women) entered the long‐term extension period (mavacamten–mavacamten, n=54; placebo–mavacamten, n=25). In the mavacamten–mavacamten group, numerical improvements in Valsalva and resting left ventricular outflow tract peak gradients were maintained through week 78 (mean change from baseline, −73.0 mm Hg [95% CI, −86.4 to −59.5]; and −56.3 mm Hg [95% CI, −67.1 to −45.5], respectively). Numerical improvements were also observed for other echocardiographic parameters, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. In the placebo–mavacamten group, numerical improvements with mavacamten in these parameters were noted from week 30 to week 78. Long‐term mavacamten treatment appeared well tolerated; left ventricular ejection fraction

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicUracilVentricular Outflow Obstruction, LeftCardiovascular AgentsHumansFemaleMiddle AgedDouble-Blind MethodMaleTreatment OutcomeChinaTime FactorsAdultVentricular Function, LeftEchocardiographyStroke VolumeAgedBiomarkersEast Asian PeopleBenzylamines

Stichwörter der Autor:innen

long‐term outcomesmavacamtenobstructive hypertrophic cardiomyopathy

Substanzen

UracilMYK-461Cardiovascular AgentsBiomarkersBenzylamines

Autor:innen und Institutionen

  • Peking Union Medical College Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
  • Renmin Hospital of Wuhan University, Hubei General Hospital Wuhan China.
  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Southern Medical University Guangzhou China.
  • West China Hospital, Sichuan University Chengdu China.
  • The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China.
  • The People's Hospital of Liaoning Province Shenyang China.

ORCID-Profile: Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian'an Wang, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, Wei Jin, Fang Wang

Zitieren

APA

Tian, Z., Li, X., Li, L., Zhang, Q., Wang, J., Shi, Y., Peng, D., Ma, W., Yang, P., Cheng, X., Jin, W., Wang, F., Xie, Y., Pan, B., Florea, V., & Zhang, S. (2026). Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study. Journal of the American Heart Association, 15(11). https://doi.org/10.1161/jaha.125.046251

Vancouver

Tian Z, Li X, Li L, Zhang Q, Wang J, Shi Y, et al. Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study. Journal of the American Heart Association. 2026;15(11). doi:10.1161/jaha.125.046251

BibTeX
@article{Tian2026,
  author = {Tian, Zhuang and Li, Xiaoyan and Li, Liwen and Zhang, Qing and Wang, Jian'an and Shi, Yunqi and Peng, Daoquan and Ma, Wei and Yang, Ping and Cheng, Xiang and Jin, Wei and Wang, Fang and Xie, Yimeng and Pan, Beth and Florea, Victoria and Zhang, Shuyang},
  title = {Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1161/jaha.125.046251}
}
Kostenlos starten →